Your browser is outdated!

To ensure you have the best experience and security possible, update your browser. Update now

×

Tomas Radvansky

Cross-Platform Mobile Developer with Medical Background

iOS
Android
Flutter
Node JS
Angular
Tomas Radvansky
36 years old
Driving License
Mangawhai Heads New Zealand
Professional Status
Employed
Open to opportunities
About Me
I'm junior doctor with full GMC registration, who loves new technologies.
Resume created on DoYouBuzz
Abstract:
Antiphospholipid syndrome (APS) is consifered as most
common acquired hypercoagulation state of autoimmune disorder in children. Besides vascular occlusion, antiphosholipid antibodies have been associated with various nonthrombotic clinical manifestations. Because of children do not suffer from the frequent thrombosis, which is due to the lack of risk factors and because of immature hemostatic and immune system, their treatment is often controversial, consisting of identifying existing risk factors, preventive medicine and the short-term treatment of thrombotic events. Clinical and laboratory characterisation of pediatric patients continues to improve and implies differences between adult and pediatric populations. Nowadays there are few reported cases of new targeted biological treatment of APS by rituximab and plasmapheresis. This article presents an overview of literary knowledge of the antiphospholipid syndrome in children, its diagnosis dependent on clinical and laboratory criteria for heterogeneous clinical manifestations, which is not completely identical to adult population and the treatment of patients with
this rare disease...